Semaglutide Superior to Liraglutide for Weight Loss
FRIDAY, Jan. 21, 2022 -- Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2022 Category: Pharmaceuticals Source Type: news

Wegovy Tops Sibling Saxenda for Weight Loss Wegovy Tops Sibling Saxenda for Weight Loss
Semaglutide was the clear weight-loss winner compared with liraglutide, from the same drug class, when added to lifestyle counseling for people with overweight/obesity but not diabetes, a study shows.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 11, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

More STEP Data: Semaglutide Cuts Weight, Cravings, Beats Liraglutide More STEP Data: Semaglutide Cuts Weight, Cravings, Beats Liraglutide
In STEP 5, weight loss with semaglutide was sustained at 2 years and the drug cut cravings in a subgroup; in STEP 8, semaglutide beat liraglutide for weight loss at 68 weeks. There were no new safety signals.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Liraglutide Effective for Weight Regain After Gastric Bypass Liraglutide Effective for Weight Regain After Gastric Bypass
In a randomized controlled trial of patients who regained weight after a gastric bypass, 69% of patients given liraglutide lost at least 5% of their weight after a year; lifestyle advice alone did not work.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 5, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

FDA approves weight management drug for patients aged 12 and older
The U.S. Food and Drug Administration has approved Saxenda (liraglutide) for chronic weight management among patients aged 12 and older who are obese. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 30, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Liraglutide Reduces Visceral Fat in Overweight, Obese Adults
WEDNESDAY, Aug. 25, 2021 -- For overweight and obese adults at high cardiovascular risk, liraglutide reduces visceral adipose tissue, according to a study published online Aug. 3 in The Lancet Diabetes& Endocrinology. Ian J. Neeland, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 25, 2021 Category: Pharmaceuticals Source Type: news

Is there any diet pill that can help you lose weight safely?
Saxenda (generic name, liraglutide) was originally developed as a drug for diabetes but has been shown to reduce body weight by, on average, 7.5 per cent in under nine months. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2021 Category: Consumer Health News Source Type: news

What's Best for Diabetes After Metformin? GRADE Outdated at Outset What's Best for Diabetes After Metformin? GRADE Outdated at Outset
The GRADE trial compared four different agents as add-ons to metformin for type 2 diabetes, and while liraglutide and insulin glargine fared best, the study is already outdated, said one commentator.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Weight-loss treatment prevents accumulation of lipid linked to cardiac mortality
(Karolinska Institutet) Researchers at the Karolinska Institutet, University of Oxford and University of Copenhagen have shown that elevated levels of lipids known as ceramides can be associated with a ten-fold higher risk of death from cardiovascular disease. Treatment with liraglutide could keep the ceramide levels in check, compared with placebo. The results have been published in the Journal of the American College of Cardiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 24, 2021 Category: International Medicine & Public Health Source Type: news

Exercise Plus Liraglutide Good for Weight Loss Maintenance Exercise Plus Liraglutide Good for Weight Loss Maintenance
Reductions in both weight and fat loss seen with exercise and liraglutide was roughly twice as much as what was achieved at 1 year with liraglutide or exercise alone.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 7, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Exercise, Liraglutide Combo Superior for Weight Loss Maintenance
THURSDAY, May 6, 2021 -- Combining exercise and liraglutide therapy improves healthy weight loss maintenance more than either strategy alone, according to a study published in the May 6 issue of the New England Journal of Medicine. Julie R.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2021 Category: Pharmaceuticals Source Type: news

Diabetes Prevention Moves Towards Reality as Studies Published Diabetes Prevention Moves Towards Reality as Studies Published
Newly published 3-year data on teplizumab in high-risk individuals and combination therapy with liraglutide in new-onset type 1 diabetes show preserving beta-cell function may be feasible.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - March 17, 2021 Category: Pediatrics Tags: Diabetes & Endocrinology News Source Type: news

FDA Approves Liraglutide for Adolescents With Obesity FDA Approves Liraglutide for Adolescents With Obesity
The new indication for liraglutide for weight loss in adolescents with obesity was welcomed as a milestone.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA approves weight management drug for patients aged 12 and older
The U.S. Food and Drug Administration has approved Saxenda (liraglutide) for chronic weight management among patients aged 12 and older who are obese. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17
PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use in the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 4, 2020 Category: Drugs & Pharmacology Source Type: news